Herren Wu

This inventor holds 50 USPTO granted patents and 40 published patent applications, plus 8 CIPO patents and 17 EPO patents, primarily in Antibody Engineering (CPC class C07K). Top assignees: Medimmune Limited, Genentech, Inc., Tanox, Inc.. Active years: 2001-2019.

USPTO Granted Patents = 50 (Patent Applications = 40)

% Patents Active = 50.0

CIPO Patents = 8 (Patent Applications = 7)

EPO Patents = 17 (Patent Applications = 20)

Average Co-Inventor Count = 3.9

ph-index = 20

Forward Citations = 947(Granted Patents)

Forward Citations (Not Self Cited) = 882(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Germantown, MD (US) (2007 - 2009)
San Diego, CA (US) (2001 - 2010)
Houston, TX (US) (2003 - 2010)
Boyds, MD (US) (2007 - 2019)
Gaithersburg, MD (US) (2013 - 2019)

Company Filing History:

Applied Molecular Evolution

The Feinstein Institutes for Medical Research

patents

8. 2 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2019

Loading Chart...

Areas of Expertise:

Antibody Engineering

High Affinity Antibodies

Humanized Antibodies

Fc Domain Modifications

Immunotherapy

Angiopoietin-2 Antibodies

Protein Scaffolds

Neutralizing Antibodies

Crystral Structure Analysis

Transplantation Treatments

Autoimmune Disease Therapy

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10329345 - Stabilized angiopoietin-2 antibodies and uses thereof (2019-06-25),

2. 10301390 - Anti-IFNAR1 antibodies with reduced Fc ligand affinity (2019-05-28),

3. 9988459 - Anti-IFNAR1 antibodies with reduced Fc ligand affinity (2018-06-05),

4. 9896505 - Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease (2018-02-20),

5. 9567389 - Cell display of antibody libraries (2017-02-14),

6. 9176129 - Protein scaffolds (2015-11-03),

7. 9156908 - High affinity, anti-human IgE antibodies (2015-10-13),

8. 8883992 - Humanized anti-CD19 antibodies (2014-11-11),

9. 8775090 - Crystals and structure of a human IgG Fc variant with enhanced FcRn binding (2014-07-08),

10. 8753826 - Methods of detecting factor D with anti-factor D antibodies (2014-06-17),

11. 8697396 - Modulation of antibody effector function by hinge domain engineering (2014-04-15),

12. 8633297 - Protein scaffolds (2014-01-21),

13. 8604171 - High affinity, anti-human IgE antibodies (2013-12-10),

14. 8507656 - Stabilized angiopoietin-2 antibodies and uses thereof (2013-08-13),

15. 8481037 - Recombinant IL-9 antibodies and uses thereof (2013-07-09),

Title: Herren Wu: Innovating Antibody Therapeutics from Boyds, MD

Introduction

Herren Wu, an accomplished inventor and innovator based in Boyds, Maryland, holds an impressive portfolio of 50 patents. His work primarily focuses on the development of advanced antibody therapeutics, demonstrating his commitment to enhancing medical treatments and therapies.

Latest Patents

Among Herren Wu's latest contributions to the field are two notable patents. The first, "Stabilized Angiopoietin-2 Antibodies and Uses Thereof," describes stabilized antibodies targeting Angiopoietin-2, along with nucleic acid and amino acid sequences, and hybridomas or other cell lines for expressing these antibodies. The second patent, "Anti-IFNAR1 Antibodies with Reduced Fc Ligand Affinity," provides a novel class of anti-IFNAR1 antibodies with reduced affinity for Fc receptors, including methods for their production and application.

Career Highlights

Herren Wu has made significant strides in his career, having worked with prestigious biopharmaceutical companies such as MedImmune Limited and Genentech, Inc. His tenure at these organizations has allowed him to contribute crucial advancements in therapeutic antibody development.

Collaborations

Throughout his career, Herren has collaborated with esteemed coworkers including William D. Huse and Peter Kiener. These partnerships have further enhanced his research and innovation in antibody therapeutics, driving the boundaries of science to improve patient outcomes.

Conclusion

Herren Wu's extensive patent portfolio and collaborations highlight his vital role in the biotech industry. His innovations in antibody therapeutics are paving the way for more effective medical solutions, demonstrating the impact one inventor can have on healthcare. Through his dedication and expertise, Herren continues to shape the future of therapeutic treatments for various diseases.